New Magnolia fund targets Dutch medtech's riskiest lab-to-company stage
What's the deal? Thuja CapitalDealroom has a profile for this one. Try Dealroom → has launched the Magnolia MedTech Fund to back early-stage medtech companies spinning out of Dutch universities and knowledge institutes. The venture fund invests in the earliest, riskiest phase, when university research must become an investable company. Its size was not disclosed.
Why now? The Dutch MedTech Growth Plan, published in December 2025, found that most of the country's dedicated medtech funds have closed in recent years. That left promising spin-outs short of the capital needed to fund clinical evidence, regulatory work, and early commercialisation.
What's the endgame? Magnolia is the investment pillar of the Thematic Technology Transfer (TTT) MedTech programme, a government initiative made possible by the Ministry of Economic Affairs and Climate Policy and coordinated by the University of Twente. It will fund devices, enabling technology, and digital health solutions built on novel technology that address a clear unmet medical need. The new round is open to cases from all Dutch universities and knowledge institutes.
Who's backing it? The fund is supported by a consortium of Dutch university medical centres and technical universities, health insurer VGZ, medical device manufacturer Nolato Unitron, Stichting Santiago, and the Netherlands Enterprise Agency. Beyond capital, its investors, management, and knowledge partners commit to hands-on coaching of founders.
Context: The fund builds on the earlier TTT MedTech programme, which produced 63 validated business cases and 22 spin-off companies, and reportedly leveraged €7 in follow-on funding for every €1 of public support. Recent examples show the appetite for small, high-risk rounds: neuroprosthetics spin-out PhosphoenixDealroom has a profile for this one. Try Dealroom → raised €1.3 million in September to prepare for first-in-human studies.
The signal: Europe attracts just 5% of global venture capital against 52% in the US, and Dutch medtech has felt that squeeze most acutely at the lab-to-company stage. Magnolia matters less as a large fundraising event than as a targeted attempt to rebuild the specialist financing that early-stage medtech has lost.
Read more: thujacapital.com
Image credit: MDGovpics
